The SIG Director oversees and supports the Special Interest Groups, in partnership with a counterpart nominated by EFSPI Council. The SIGs drive discussion and capability development across many topics of interest to PSI members, supporting the wider community through the development of papers, putting on webinars and contributing to events such as PSI Conference.
Please click here to view the job specification for this role.
Volunteering for the PSI Board of Directors is a rewarding and challenging opportunity to contribute to the profession and the community. You will also gain valuable skills and experience and expand your network. We welcome applications from all PSI members who share our vision and values, and who have the time and dedication to serve on the Board.
If you are interested in any of these positions, please download and complete this form and return it to psi@mci-group.com. We would also welcome your questions on this email address if you would like to discuss any of the above before applying.
Applicants must be a member of PSI. All nominations will need a proposer who is a full member of PSI (a current or past Board member of PSI is preferred). All completed applications must be received by Tuesday 9 April 2024, with results officially announced at the PSI AGM on Tuesday 18 June 2024.
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
The event will open with an overview on drug development in women’s health from a clinician perspective. This talk is followed by talks about statistical challenges when planning IVF studies and analysing the menstrual cycles.
This webinar will provide an overview of surrogacy for licensing and reimbursement. In turn, the need of extensions of the SPIRIT and CONSORT statement will be defined and outlined, with case studies to support.
Lea Vaas will present how replacement of concurrent control animals by Virtual Control Groups (VCGs) in systemic toxicity studies may help in contributing to the 3R's principle of animal experimentation: Reduce, Refine, Replace.
We will share a brief overview of what Mobilise D is and why it is an important step stone in the development of digital biomarkers, and how Mobilise D outputs can be relevant for you.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This webinar will cover the history of cell/gene therapy, major regulatory advances, the role of quantitative scientists in drug development of these novel therapeutics, and discuss opportunities for innovation and product advancement.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
We have exciting new opportunities available for Study Statisticians, Support Statisticians and Exploratory Statisticians at various levels.
